Tissue Microarray Global Market Report 2024

The tissue microarray market size has grown rapidly in recent years. It will grow from $11.17 billion in 2023 to $12.36 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed in the historical period can be attributed to factors such as the rise of precision medicine, advancements in drug discovery and development, the efficient analysis enabled by tissue microarrays, the increasing prevalence of chronic diseases, and initiatives in biobanking.

The tissue microarray market size is expected to see rapid growth in the next few years. It will grow to $18.68 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The anticipated growth in the forecast period can be attributed to factors such as the emergence of digital pathology, expanded applications of tissue microarrays, the growth of the biopharmaceutical industry, regulatory support and standards, and the integration of artificial intelligence (AI) and machine learning. Noteworthy trends in the forecast period include advancements in imaging technologies, the development of 3D tissue microarrays, the adoption of high-content screening, standardization initiatives, and the integration of single-cell analysis methods.

The tissue microarray market is poised for growth, driven by the increasing number of cancer cases. Cancer, characterized by abnormal cell proliferation and invasion, necessitates advanced diagnostic tools. Tissue arrays play a crucial role in oncology by examining cancer-related biomarkers in various tumor samples. According to the American Cancer Society Inc., it is estimated that there will be 609,820 cancer deaths and 1,958,310 new cancer cases in the US during 2022, underscoring the demand for tissue microarrays in cancer research and diagnosis.

The growth of the tissue microarray market is further fueled by the rising demand for personalized medicine. Personalized medicine tailors medical treatment to individual characteristics for more effective healthcare. Tissue microarrays are instrumental in analyzing multiple tissue samples concurrently, facilitating rapid assessment of biomarkers. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines. This emphasizes the integral role of tissue microarrays in advancing personalized medicine.

A notable trend in the tissue microarray market is the emergence of strategic partnerships. Major companies in the market are forming alliances to develop innovative tissue microarray technologies. For instance, The Cureline Group partnered with Cellecta Inc. to launch Tissue 2 Target Services, combining their competencies in molecular analysis and biospecimen management. Another collaboration involves Ultivue Inc. and ngTMA, aiming to advance multiplexed immunofluorescence assays and apply new tissue microarray technologies for spatial analysis in scientific research.

Companies in the tissue microarray market are focusing on advanced solutions, such as microarray platforms, to enhance precision and efficiency in high-throughput tissue analysis. MARGenomics launched the Applied Biosystems GeneChip 3000 Dx v2, an advanced microarray platform, the first in Europe and the United States to receive regulatory approval for diagnostic purposes. This platform, funded by the Carlos III Health Institute and the European Union's NextGenerationEU initiative, offers diverse functionalities for genomic and expression microarrays.

In July 2021, BioIVT acquired Tissue Solutions Ltd., expanding access to high-quality disease state and control biospecimens. Tissue Solutions Ltd., a virtual biobank based in the UK, provides human tissue and biological materials to researchers for various applications, including drug discovery, target identification, assay creation, and biomarker development. This acquisition enhances BioIVT's capabilities and geographic reach with an addition of 150 collection sites.

Major companies operating in the tissue microarray market report are Roche Group, Merck & Co. Inc., Thermo Fisher Scientific Inc., Becton, Dickinson Biosciences, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, PerkinElmer Inc., Bio-Techne Corporation, Tristar Group, Evotec SE, Precision For Medicine Inc., Molecular Devices LLC, BioIVT LLC, BioChain Institute Inc., Creative Bioarray Co, 3DHISTECH Ltd., Novus Biologicals LLC, OriGene Technologies Inc., PREMIER Biosoft International Inc., iSpecimen Inc., OriGene Technologies Inc., Bio SB Inc., ProteoGenex Inc., Z Biotech LLC.

North America was the largest region in the tissue microarray market in 2023. Asia-Pacific is expected to be the fastest-growing region in the tissue microarray market report during the forecast period. The regions covered in the tissue microarray market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tissue microarray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of tissue microarrays include immunohistochemistry, fluorescent in situ hybridization, frozen tissue array, and other variants. Immunohistochemistry (IHC) is a technique used to diagnose certain types of cancer, such as mesothelioma, by employing a visual marker to locate antigens in biopsy tissue. Various technologies such as DNA microarrays, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, western blotting, and others are utilized for applications in oncology, gene expression profiling, single nucleotide polymorphism (SNP) detection, double-stranded B-DNA microarrays, comparative genomic hybridization, sequencing bioinformatics, and more. These technologies find applications across different end-users, including pharmaceutical and biotechnological companies, research organizations, and hospitals.

The tissue microarray research report is one of a series of new reports that provides tissue microarray market statistics, including the tissue microarray industry's global market size, regional shares, competitors with tissue microarray market share, detailed tissue microarray market segments, market trends and opportunities, and any further data you may need to thrive in the tissue microarray industry. This tissue microarray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tissue microarray market consists of sales of molds, needles, and tissue punches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.